NO20070567L - Behandling av bakterielle infeksjoner - Google Patents

Behandling av bakterielle infeksjoner

Info

Publication number
NO20070567L
NO20070567L NO20070567A NO20070567A NO20070567L NO 20070567 L NO20070567 L NO 20070567L NO 20070567 A NO20070567 A NO 20070567A NO 20070567 A NO20070567 A NO 20070567A NO 20070567 L NO20070567 L NO 20070567L
Authority
NO
Norway
Prior art keywords
treatment
bacterial infections
relates
infection
faecium
Prior art date
Application number
NO20070567A
Other languages
English (en)
Norwegian (no)
Inventor
James Peter Burnie
Ruth Christine Matthews
Tracey Carter
Original Assignee
Neutech Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutech Pharma Plc filed Critical Neutech Pharma Plc
Publication of NO20070567L publication Critical patent/NO20070567L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20070567A 2004-07-02 2007-01-30 Behandling av bakterielle infeksjoner NO20070567L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0414886.2A GB0414886D0 (en) 2004-07-02 2004-07-02 Treatment of bacterial infections
PCT/GB2005/002607 WO2006003426A1 (fr) 2004-07-02 2005-07-01 Traitement des infections bactériennes

Publications (1)

Publication Number Publication Date
NO20070567L true NO20070567L (no) 2007-01-30

Family

ID=32843487

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070567A NO20070567L (no) 2004-07-02 2007-01-30 Behandling av bakterielle infeksjoner

Country Status (19)

Country Link
US (1) US7608265B2 (fr)
EP (1) EP1763539A1 (fr)
JP (1) JP2008505621A (fr)
KR (1) KR20070038539A (fr)
CN (1) CN101014621A (fr)
AU (1) AU2005258938A1 (fr)
BR (1) BRPI0512740A (fr)
CA (1) CA2569557A1 (fr)
EC (1) ECSP077220A (fr)
GB (1) GB0414886D0 (fr)
IL (1) IL180459A0 (fr)
MA (1) MA28694B1 (fr)
MX (1) MXPA06015081A (fr)
NO (1) NO20070567L (fr)
NZ (1) NZ552110A (fr)
RU (1) RU2377251C2 (fr)
TN (1) TNSN06453A1 (fr)
WO (1) WO2006003426A1 (fr)
ZA (1) ZA200610279B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
EP2806882B1 (fr) 2012-01-23 2018-11-14 Santalis Pharmaceuticals Inc. Huile de bois de santal et ses utilisations afférentes aux infections à clostridium
WO2014085821A2 (fr) * 2012-11-30 2014-06-05 The Regents Of The University Of California Anticorps entièrement humains et fragments reconnaissant la protéine c-met humaine
CN103044527B (zh) * 2012-12-21 2014-08-06 南昌大学 庆大霉素的抗原模拟表位及其应用
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
KR102487338B1 (ko) * 2020-12-18 2023-01-12 한국지질자원연구원 점토광물 복합체를 포함하는 cdi 치료용 약학적 조성물 및 그 제조방법
US20250230260A1 (en) * 2022-04-15 2025-07-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cdrs for glycosylated acat1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
CA2006878A1 (fr) 1988-12-29 1990-06-29 John D. Rodwell Systemes de caracterisation moleculaire
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
DE69619894T2 (de) * 1995-06-30 2002-11-14 American Cyanamid Co., Madison Stabile Makrolide und Makrolide Imptstoff-Zusammensetzungen
GB9621295D0 (en) 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1024826B1 (fr) 1997-10-20 2005-03-16 Acambis, Inc. Immunisation passive contre la maladie de clostridium difficile
DE69901569T2 (de) 1998-08-28 2002-12-19 Genentech, Inc. Humane antikörper gegen faktor ix/ixa
AU7676300A (en) 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
AU770115B2 (en) 1999-12-13 2004-02-12 Cambridge Antibody Technology Limited Brain specific binding members
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
DE60124313T2 (de) 2001-01-15 2007-05-31 Keryos S.P.A. Dns-vakzine von hypervariablen vh-cdr3 idiotypischen determinanten
US20030054009A1 (en) 2001-02-09 2003-03-20 Windle Henry J. Clostridium difficile vaccine
EP1461428B1 (fr) * 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Méthode de production d'anticorps hybrides
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies

Also Published As

Publication number Publication date
EP1763539A1 (fr) 2007-03-21
MXPA06015081A (es) 2007-07-20
TNSN06453A1 (en) 2008-02-22
RU2377251C2 (ru) 2009-12-27
KR20070038539A (ko) 2007-04-10
MA28694B1 (fr) 2007-06-01
IL180459A0 (en) 2007-06-03
AU2005258938A1 (en) 2006-01-12
RU2007104033A (ru) 2008-08-10
GB0414886D0 (en) 2004-08-04
ZA200610279B (en) 2008-08-27
JP2008505621A (ja) 2008-02-28
CN101014621A (zh) 2007-08-08
CA2569557A1 (fr) 2006-01-12
WO2006003426A1 (fr) 2006-01-12
NZ552110A (en) 2010-11-26
ECSP077220A (es) 2007-03-29
US7608265B2 (en) 2009-10-27
BRPI0512740A (pt) 2008-04-08
US20080038266A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
NO20070782L (no) Tetrapeptidanaloger.
UA110199C2 (xx) Тверда дисперсія рифаксиміну
NO20082414L (no) Inhibitorer av AKT-aktivitet
DK2109602T3 (da) Tetracyclinderivater til behandling af bakterielle, virale og parasitiske infektioner
NO20082531L (no) Neuropilinantagonister
NO20093060L (no) Spirosykliske sykloheksanderivater
EA200970738A1 (ru) Ингибиторы активности akt
DK1789419T3 (da) Gyraseinhibitorer og anvendelser deraf
NO20090052L (no) Nye forbindelser
NO20052362D0 (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
DE50306587D1 (de) Antibakterielle amid-makrozyklen
DK2126049T3 (da) Antistoffer mod humant cytomegalovirus (hCMV)
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
ECSP077220A (es) Tratamiento de infecciones bacterianas
MX2009012767A (es) Metodos de tratamiento de infecciones fungicas.
NO20083751L (no) Metoder for behandling av kognitive og andre sykdommer
NO20072890L (no) Behandling av mastitt
WO2007047608A3 (fr) Substances therapeutiques ciblees sur la fibrine
ATE510845T1 (de) Antibakterielle makrozyklen mit substituiertem biphenyl
CL2007001910A1 (es) Compuestos derivados de penem; composicion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
NO20071706L (no) Koadministrering av Tigecycline og Digoxin.
ATE497392T1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
ATE524488T1 (de) Lysobactinamide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application